Bluebush I really had the broker road show and media style marketing in mind when I mentioned this as well as funding from Government of other bodies who would be pleased to be involved - or even a corner stone investor
I think Steve will re-affirm the results of the 2a trials and that they have seen no reason for these results not to be borne out by the phase 3 trials that Artimist is superior to Intravenous Quinine
All in all the ducks are lining up - EMS (SUDA) is becoming a strong buy in my view
Clyde
EMS Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held